Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study

Background: New glucose-lowering drugs have shown benefits regarding cardiovascular events, heart failure, and kidney-related outcomes in type 2 diabetes (T2D). This study aimed to estimate the adequacy of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) prescription to people living...

Descripción completa

Detalles Bibliográficos
Autores principales: Simões de Carvalho, Francisco, de Brito Marques, Francisca, Lopes, Ana Elisa, Lima Ferreira, Joana, Príncipe, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826698/
https://www.ncbi.nlm.nih.gov/pubmed/36628395
http://dx.doi.org/10.7759/cureus.33509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826698/
https://www.ncbi.nlm.nih.gov/pubmed/36628395
http://dx.doi.org/10.7759/cureus.33509

Ejemplares similares